Karen Mann, MD [Chair] ('14)
Kojo S. J. Elenitoba-Johnson, MD [Vice Chair] ('14)
Randy D. Gascoyne, MD ('15)
Torsten Haferlach, MD ('17)
Inga Hofmann, MD ('17)
Eric Hsi, MD ('16)
Teresa S. Kraus, MD ('14)
Karen P. Mann, MD, PhD ('14)
Stefania Pittaluga, MD, PhD ('15)
Maria A. Proytcheva, MD ('16)
Henry Rinder, MD ('14)
The Scientific Committee on Hematopathology and Clinical Laboratory Hematology is focused on the scientific underpinnings of modern laboratory diagnostics, relevant to the care of patients with benign and malignant hematological disorders.
The committee will focus on emerging ideas in the pathophysiology of these disorders that lend themselves to diagnostic applications and on evolving novel technologies which are predicted to transition into the clinical laboratory.
The clinical areas for this committee are the diverse hematological disorders that require laboratory assessments for diagnosis, monitoring, treatment, and/or prognosis.
The methodological aspects are centered on state-of-the-art research technologies, and emerging diagnostic methodologies, that can be expected to affect routine clinical diagnostics in the future.
The emerging areas, relevant for diagnostic technologies, include the application of somatic mutation evaluation, gene expression profiles, copy number variations, single nucleotide polymorphisms, next generation sequencing, proteomics, and metabolomics to diagnosing, treating, and monitoring all types of benign and malignant hematological diseases.
The Committee’s interest is ongoing clinical research that informs optimal testing methodologies for improved laboratory diagnosis, monitoring or management of blood disorders.
The Committee’s focus on diagnostics, rather than a specific field of hematology, means that it has the potential to overlap with all of the other ASH Scientific Committees.
Thus, appropriate sessions for this Committee at the ASH annual meeting may include laboratory technologies applicable to many fields within hematology, with a focus on laboratory methods that are grounded either in an improved pathophysiological understanding of blood disorders or in novel technologies. Through Scientific Program sessions at the Annual Meeting, the Committee will educate the membership regarding how new technological approaches may be transitioned from discovery tools to the diagnostic setting, and identify technological, procedural, analytic and regulatory issues that must be addressed. The implementation of genomic testing techniques into routine clinical diagnostics is an example of a high priority area to be addressed by the Committee.
back to top